Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue-
EPS-$0.09In line
EPS estimate-$0.09

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$755.6K
EPS estimate-$0.14

Financials

Q3 2025

Income statement

See full
Revenue--100%
Operating income-$34.0M-31.4%
Net income-$32.7M-28.2%
EPS (diluted)-$0.09+10.0%

Balance sheet

See full
Cash & equivalents$297.3M+88.6%
Total debt$69.1M+9.6%
Total equity$219.0M+147%
Total assets$316.6M+75.7%

Cash flow

See full
Operating cash flow-$24.2M-11.8%
CapEx$108.0K+209%
Free cash flow-$24.3M-12.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$892.04M+119%
Enterprise value$663.78M+112%
P/S141.4×+100×

Profitability

See full
Operating margin-1,618.5%+7,810pp
Net margin-1,583.7%—
FCF margin-1,349.6%+2,932pp

Returns & leverage

See full
Return on equity-64.9%—
Debt / equity0.3×-0.4×
Current ratio10.5×+5.0×

FAQ

When did Taysha Gene Therapies, Inc. report Q3 2025 earnings?
Taysha Gene Therapies, Inc. (TSHA) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Taysha Gene Therapies, Inc.'s Q3 2025 revenue and EPS?
Taysha Gene Therapies, Inc. reported revenue of - and eps of $-0.09 for Q3 2025.
Did Taysha Gene Therapies, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.09 by $0.00.
How did Taysha Gene Therapies, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $1.8M a year earlier and eps grew 0.0% from $-0.09.
Where can I find Taysha Gene Therapies, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-263543) and the 10-Q periodic report (0001193125-25-263506) directly on SEC EDGAR. The filing index links above go to sec.gov.